All News


ePT--the Electronic Newsletter of Pharmaceutical Technology

Bristol-Myers Squibb (New York) has agreed to acquire the biopharmaceutical company ZymoGenetics (Seattle) for an aggregate purchase price of $885 million or $735 million net of cash.

ePT--the Electronic Newsletter of Pharmaceutical Technology

The generic-drug company Actavis (Hafnarfjordur, Iceland) is considering acquiring a 51% stake in the biopharmaceutical company BioPartners Holdings (Barr, Switzerland) from Bioton, a Polish biotechnology company.

ePT--the Electronic Newsletter of Pharmaceutical Technology

After hosting the first international scientific workshop on nanomedicines earlier this month, the European Medicines Agency (EMA) has concluded that further research is needed to provide an adequate scientific basis for evaluating the quality, safety, and efficacy of such medicines.

ePT--the Electronic Newsletter of Pharmaceutical Technology

Director General of the European Generic Medicines Association (EGA), Greg Perry, has emphasized the need for EU biosimilar guidelines for monoclonal antibodies (mAbs), as well as a harmonized, global approach to biosimilars in general, at the agency's 8th International Symposium on Biosimilar Medicines.

Pharmaceutical Technology Europe

The European Medicines Agency (EMA) has launched a review of GlaxoSmithKline's pandemic influenza vaccine Pandemrix to investigate whether there is a link between vaccination and cases of narcolepsy, a rare sleep disorder.

i1-685639-1408626165466.jpg

No More Exceptions

From weekend deliveries to nonsterile gloves, a single exception can make a product fall flat.

i1-685887-1408626018875.jpg

Industry participation is crucial as USP embarks on far-reaching monograph modernization initiative. This is an online-exclusive article.

i1-685047-1408626720095.jpg

Pharmaceutical Technology Europe

No one can deny the power of social media; it has revolutionised communication and empowered consumers, creating a medium that allows the free flow of information with no authority to control it.